close
Add to watchlist
Cerus Corp (CERS) Healthcare, Biotechnology & Drugs
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company's INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.94 |
| Volume | 875115 |
| Volume Avg | 514961 |
| 52 Week High | 4.09 |
| 52 Week Low | 1.92 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.35 |
| EPS change Q/Q | -83.33% |
| EPS change Q/Q Yr ago | -21.43% |
| EPS change Q/Q next Q est | -37.5% |
| EPS change Y/Y | -51.22% |
| REV change Q/Q | 1.54% |
| REV change Q/Q Yr ago | 15.79% |
| EPS next Q est | -0.08 |
| EPS next Y est | -0.26 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |